fb-pixelThe Latest in Financial & Business News - The Boston Globe Skip to main content

Drug giant Takeda plans more than 640 layoffs in Massachusetts

The state's largest drug maker by headcount confirmed Friday that it plans to lay off hundreds of local employees between early July and next March.

RHODE MAP
A sneak peek at the Rhode Island Life Sciences Hub summit
Hundreds of policymakers, thought leaders, and politicians are coming together at the R.I. convention center to discuss where Rhode Island fits in a multibillion-dollar industry.

Moderna wins a battle in vaccine patent dispute with Pfizer-BioNTech
The Cambridge biotech said Friday that the European Patent Office has upheld the validity of one of its key patents, a victory in an ongoing dispute with Pfizer and BioNTech over rival COVID-19 vaccines.

Ginkgo Bioworks stock threatened with delisting
The once-high-flying Boston life sciences firm has had an average closing price of less than $1 per share over 30 consecutive days of trading.

Ginkgo Bioworks to slash labor costs, jobs
After lackluster first-quarter earnings, Ginkgo Bioworks said it will slash labor expenses by at least 25 percent, which will include an unspecified number of job cuts.

Moderna’s mRNA dreams meet reality with first post-COVID shot
The Cambridge biotech's second vaccine, for RSV, is its first chance to show the versatility of mRNA technology to more effectively treat and prevent a range of illnesses from the flu to cancer.

Moderna’s COVID vaccine sales plunge, as analysts debate future of once-hot company
The decline in sales illustrates waning demand for protection from the virus that caused the pandemic.

FDA approves Boston biotech’s drug for ultra-rare disease of immune system
X4 Pharmaceuticals said regulators approved Xolremdi for use in patients 12 years and older with WHIM syndrome, which can make you more vulnerable to infections.

More Life Sciences Headlines

Deciphera to be acquired by Japanese drug firm for $2.4 billion

Ono Pharmaceutical will pay $25.60 per Deciphera share in cash, a premium of nearly 75 percent on the Waltham cancer biotech’s closing price of $14.65 on Friday.

Biogen stock climbs on strong Alzheimer’s drug sales

The Cambridge firm on Wednesday reported a first-quarter profit that exceeded estimates as it cut costs and sales of its closely watched Alzheimer’s drug, Leqembi, surpassed expectations.

Sage Therapeutics stock plunges 20 percent after Parkinson’s drug fails study

It was the latest setback for the Cambridge biotech, which in August announced it would lay off 40 percent of its workforce.

Neumora Therapeutics shares fall after rabbits dosed with schizophrenia drug have convulsions

Shares of Neumora Therapeutics fell more than 15 percent Monday morning after an announcement that a clinical trial was paused.

Doctors protest cost of Vertex cystic fibrosis drug as its scientists prepare to receive $3 million ‘Oscars of Science’ award

The controversy threatened to mar a celebrity-studded celebration for researchers who developed new life-saving drugs.

Vertex buying Seattle biotech for $4.9 billion, its biggest acquisition ever

The Boston-based drug company is acquiring Alpine Immune Sciences, a developer of immunotherapies, for $65 a share.

Seaport Therapeutics has $100 million to develop new ways to treat mental disorders

The founders of Karuna Therapeutics, the Boston biotech that was bought by Bristol Myers Squibb for $14 billion, have launched a new company.

Cambridge firm Amylyx pulls ALS drug from market, lays off 70 percent of its staff

The move comes four weeks after the biotech reported that its controversial and costly drug for amyotrophic lateral sclerosis failed to provide any benefit to patients in a large clinical trial.